Literature DB >> 12298119

Switching from i.v. to s.c. epoetin in hemodialysis patients.

Michael D Knauss, Ted Walton, Edwin J Macon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12298119     DOI： 10.1093/ajhp/59.18.1783

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

2.  Route of epoetin administration influences hemoglobin variability in hemodialysis patients.

Authors:  Tejas Patel; Angie Hirter; James Kaufman; Sai Ram Keithi-Reddy; Domenic Reda; Ajay Singh
Journal:  Am J Nephrol       Date:  2008-10-21       Impact factor: 3.754
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.